Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Imunon (IMNN) has provided an announcement.
Imunon, Inc. has revealed encouraging results from its Phase 2 OVATION 2 trial, which tested IMNN-001 alongside standard chemotherapy treatments for advanced ovarian cancer. The data indicates that the treatment could potentially extend the median time to event and improve overall survival rates, although statistical significance was not reached. Investors and interested parties are invited to a conference call and can access more information via a webcast or the investor presentation on the company’s website.
For an in-depth examination of IMNN stock, go to TipRanks’ Stock Analysis page.